Focus: Debiopharm is a Swiss-based Contract Development & Manufacturing Organization (CDMO) specializing in oncology, infectious diseases, and other therapeutic areas with a lean team of 1-50 employees. The company operates as a private entity focused on drug development and manufacturing services.
Profile data last refreshed 13h ago · AI intelligence enriched 18h ago
Debiopharm offers early-stage drug development exposure and CDMO specialization in a private Swiss biotech, but lacks financial transparency and scale to compete with established CDMOs or mid-cap biotechs for career security and advancement.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Debiopharm
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Debiopharm's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
FluoSphera partners with Debiopharm and Leica Microsystems - Greater Geneva Bern area (GGBa)
FluoSphera partners with Debiopharm and Leica Microsystems Greater Geneva Bern area (GGBa)
FluoSphera Licenses Debiopharm’s AbYlink™ Technology for 3D Antibody Characterization while Leveraging Leica Microsystems Viventis Deep Imaging Capabilities - Business Wire
FluoSphera Licenses Debiopharm’s AbYlink™ Technology for 3D Antibody Characterization while Leveraging Leica Microsystems Viventis Deep Imaging Capabilities Business Wire
Q&A: Aprea Therapeutics' Oren Gilad on WEE1 Inhibitor Data and the Company's DNA Damage Response Strategy - BioPharm International
Q&A: Aprea Therapeutics' Oren Gilad on WEE1 Inhibitor Data and the Company's DNA Damage Response Strategy BioPharm International
Octozi Raises $3M in Seed Funding to bring Agentic AI to Clinical Development - tradingview.com
Octozi Raises $3M in Seed Funding to bring Agentic AI to Clinical Development tradingview.com
Exclusive: How a Swiss pharma got to Octozi’s cap table before any US VC did - Tech Funding News
Exclusive: How a Swiss pharma got to Octozi’s cap table before any US VC did Tech Funding News
Octozi Raises $3M in Seed Funding to bring Agentic AI to Clinical Development - GlobeNewswire
Octozi Raises $3M in Seed Funding to bring Agentic AI to Clinical Development GlobeNewswire
Showing 6 of 10 news items
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo